Koichiro Kase
About Koichiro Kase
Koichiro Kase is a Senior Director at Insmed Incorporated, with extensive experience in pharmaceutical regulatory affairs and CMC sciences. He has held various leadership roles in prominent companies, including CSL Behring and Janssen, and holds a Ph.D. in Material Sciences from Kyoto Institute of Technology.
Work at Insmed
Koichiro Kase currently serves as Senior Director at Insmed Incorporated, a position he has held since 2022 in Tokyo, Japan. Prior to this role, he worked as Director of CMC Regulatory Affairs at Insmed from 2020 to 2022. His tenure at Insmed has contributed to the company's focus on advancing innovative therapies.
Previous Experience at CSL Behring
Before joining Insmed, Koichiro Kase worked at CSL Behring as Head of CMC Regulatory Affairs from 2019 to 2020 for eight months in Tokyo, Japan. In this role, he was responsible for overseeing the regulatory aspects of the chemistry, manufacturing, and controls processes.
Experience at Janssen
Koichiro Kase held the position of Director of CMC Sciences at Janssen, Pharmaceutical Companies of Johnson and Johnson from 2012 to 2019 in Tokyo, Japan. His responsibilities included managing the scientific and regulatory components of CMC, focusing on the development of pharmaceutical products.
Educational Background
Koichiro Kase studied at Kyoto Institute of Technology, where he earned a Ph.D. in Material Sciences from 1996 to 2000. He also obtained a Bachelor of Arts degree from the same institution, studying from 1977 to 1981. His educational background has provided a strong foundation for his career in pharmaceutical sciences.
Career at Merck & Co. and Schering-Plough
Koichiro Kase has held significant roles at Merck & Co. Inc (MSD) and Schering-Plough Research Institute. He worked as a Fellow in Pharmaceutical CMC at Merck from 2009 to 2011 in the United States. At Schering-Plough, he served as Senior Principal Scientist in Pharmaceutical Science from 2002 to 2007 and as Fellow in Pharmaceutical Science from 2007 to 2009, contributing to various pharmaceutical development projects.